当前位置: X-MOL 学术Virchows Arch. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Expression of potential therapeutic target SSTR2a in primary and metastatic non-keratinizing nasopharyngeal carcinoma.
Virchows Archiv ( IF 3.4 ) Pub Date : 2020-04-23 , DOI: 10.1007/s00428-020-02815-7
Lili Tao 1 , Yaoli Chen 1 , Xiaoxin Shi 1 , Guangyin Yu 1 , Weihua Yin 1 , Yuhua Huang 2, 3
Affiliation  

Somatostatin receptor 2a (SSTR2a) is an important diagnostic and scintigraphic marker in several tumors, as well as a potential therapeutic target. However, the expression and clinicopathologic significance of SSTR2a in nasopharyngeal carcinoma (NPC) remain unknown. The expression of SSTR2a was retrospectively analyzed in a large series of NPC tissue samples (106 primary NPC samples, comprising 99 primary non-keratinizing NPC (NK-NPC) and 7 keratinizing NPC (K-NPC) samples, and 41 metastatic NPC samples) by immunohistochemistry, with 24 cases of normal nasopharyngeal mucosa tissues used as a control group. Normal epithelia in nasopharyngeal mucosa were negative for SSTR2a in all 24 cases. The expression of SSTR2a in primary NPC was correlated to the histological subtype. Most cases of primary NK-NPC showed expression of SSTR2a (93.9%, 93/99 cases). The percentage of SSTR2a-positive tumor cells ranged from 10 to 100%, while the intensity ranged from 2+ to 4+. None of the primary K-NPC samples showed SSTR2a expression (0/7, 100%). All cases of NPC showed negative expression of other neuroendocrine markers, including synaptophysin, chromogranin A, and CD56. Of all 41 cases of metastatic NK-NPC lesions, SSTR2a expression is concordant with that of the primary lesions, which shows statistical significance (p < 0.001). Our observations expand the spectrum of recognized SSTR2a-positive tumors and demonstrate for the first time that SSTR2a is frequently expressed in primary and metastatic NK-NPC, highlighting its potential as a scintigraphic and therapeutic target in this disease.

中文翻译:

潜在治疗靶标SSTR2a在原发性和转移性非角化性鼻咽癌中的表达。

生长抑素受体2a(SSTR2a)是几种肿瘤的重要诊断和闪烁显像标记,也是潜在的治疗靶标。然而,SSTR2a在鼻咽癌(NPC)中的表达及其临床病理意义仍然未知。回顾性分析了大系列NPC组织样本(106个原发性NPC样本,其中包括99个原发性非角化NPC(NK-NPC)和7个角化化NPC(K-NPC)样本,以及41个转移性NPC样本)中SSTR2a的表达。通过免疫组织化学法,以24例正常的鼻咽粘膜组织作为对照组。鼻咽粘膜的正常上皮在所有24例中均为SSTR2a阴性。SSTR2a在原发性鼻咽癌中的表达与组织学亚型相关。大多数原发性NK-NPC病例显示SSTR2a表达(93.9%,93/99例)。SSTR2a阳性肿瘤细胞的百分比范围从10%到100%,而强度范围从2+到4+。没有一个主要的K-NPC样品显示SSTR2a表达(0 / 7,100%)。所有NPC病例均显示其他神经内分泌标记物,包括突触素,嗜铬粒蛋白A和CD56阴性表达。在所有41例转移性NK-NPC病变中,SSTR2a的表达与原发性病变一致,具有统计学意义(p <0.001)。我们的观察扩大了公认的SSTR2a阳性肿瘤的范围,并首次证明SSTR2a在原发性和转移性NK-NPC中频繁表达,突出了其作为该疾病的闪烁显像和治疗靶标的潜力。没有一个主要的K-NPC样品显示SSTR2a表达(0 / 7,100%)。所有NPC病例均显示其他神经内分泌标记物,包括突触素,嗜铬粒蛋白A和CD56阴性表达。在所有41例转移性NK-NPC病变中,SSTR2a的表达与原发性病变一致,具有统计学意义(p <0.001)。我们的观察扩大了公认的SSTR2a阳性肿瘤的范围,并首次证明SSTR2a在原发性和转移性NK-NPC中频繁表达,突出了其作为该疾病的闪烁显像和治疗靶标的潜力。没有一个主要的K-NPC样品显示SSTR2a表达(0 / 7,100%)。所有NPC病例均显示其他神经内分泌标记物,包括突触素,嗜铬粒蛋白A和CD56阴性表达。在所有41例转移性NK-NPC病变中,SSTR2a的表达与原发性病变一致,具有统计学意义(p <0.001)。我们的观察扩大了公认的SSTR2a阳性肿瘤的范围,并首次证明SSTR2a在原发性和转移性NK-NPC中频繁表达,突出了其作为该疾病的闪烁显像和治疗靶标的潜力。在所有41例转移性NK-NPC病变中,SSTR2a的表达与原发性病变一致,具有统计学意义(p <0.001)。我们的观察扩大了公认的SSTR2a阳性肿瘤的范围,并首次证明SSTR2a在原发性和转移性NK-NPC中频繁表达,突出了其作为该疾病的闪烁显像和治疗靶标的潜力。在所有41例转移性NK-NPC病变中,SSTR2a的表达与原发性病变一致,具有统计学意义(p <0.001)。我们的观察扩大了公认的SSTR2a阳性肿瘤的范围,并首次证明SSTR2a在原发性和转移性NK-NPC中频繁表达,突出了其作为该疾病的闪烁显像和治疗靶标的潜力。
更新日期:2020-04-24
down
wechat
bug